 | | Vol. 9.47 – 8 December, 2021 |
| |
|
|
| The authors immunized rhesus macaques and assessed immune responses over one year in blood, upper and lower airways.
[Cell] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists evaluated longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who had experienced COVID-19, compared to 21 adults who did not have prior COVID-19.
[Science Translational Medicine] |
|
|
|
| While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naïve individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals.
[Cell Host & Microbe] |
|
|
|
| Investigators developed a spherical cocktail neutralizing aptamer-gold nanoparticle to block the interaction between the receptor-binding domain of SARS-CoV-2 and host ACE2.
[Journal of the American Chemical Society] |
|
|
|
| The authors assessed low-dose immunization with lyophilized nanoparticles decorated with recombinant SARS-CoV-2 antigens.
[Science Advances] |
|
|
|
| Researchers assessed the immunogenicity and protective efficacy of sCPD9 in the Roborovski dwarf hamster, a nontransgenic rodent species that was highly susceptible to SARS-CoV-2 and severe COVID-19–like disease.
[Science Advances] |
|
|
|
| Scientists applied single-cell RNA sequencing and proteomics to a primary cell model of human nasal epithelium differentiated at air-liquid interface. SARS-CoV-2 demonstrated widespread tropism for nasal epithelial cell types.
[Nature Communications] |
|
|
|
| Researchers identified nonmuscle myosin heavy chain IIA as an important host factor for SARS-CoV-2 infection of human pulmonary cells by using APEX2 proximity-labeling techniques.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors compared serology results of paramedics vaccinated with mRNA vaccines at the recommended short vs long interval.
[Clinical infectious Diseases] |
|
|
|
| To evaluate the yield and immunogenicity of different forms of the viral spike (S) protein, scientists constructed modified vaccinia virus Ankara (MVA) vectors expressing full-length S, the RBD, and soluble S ectodomain and tested their immunogenicity in dose-ranging studies in mice.
[NPJ Vaccines] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| The authors investigated the impact of repeated P. falciparum infections on human γδ T cells in the context of natural infection in Malian children and adults, as well as serial controlled human malaria infection of US adults, some of whom became clinically immune to malaria.
[Science Translational Medicine] |
|
|
|
| Investigators found that monophosphoryl lipid A (MPLA) self-assembled with saponins to form particles physically resembling immune-stimulatory complexes, which they termed saponin/MPLA nanoparticles.
[Science Immunology] |
|
|
|
| Scientists found that BMP9/BMP10-ALK1 signaling controlled the identity and self-renewal of Kupffer cells through a Smad4-dependent pathway.
[Journal of Clinical Investigation] |
|
|
|
| Investigators used flow cytometry, T cell receptor sequencing, single-cell transcriptomics, and cytokine analysis to profile virus-specific CD8+ T cells recognizing the ubiquitous pathogens influenza and cytomegalovirus.
[Cell Reports] |
|
|
|
| The authors reported that unlike susceptible C57BL/6J mice, A/J mice were highly resistant to secondary infection.
[PLoS Pathogens] |
|
|
|
|
| A brief account of the polymorphism in the APOBEC3G, TRIM5α, and BST2 genes are explored among different populations along with the interaction of APOBEC3G with Vif protein.
[Microbial Pathogenesis] |
|
|
|
|
| Todos Medical, Ltd. together with its 3CL biology-focused joint venture partner NLC Pharma, announced that all 31 patients enrolled to date in Tollovir® Phase II clinical trial in hospitalized COVID-19 patients completed study participation.
[Todos Medical, Ltd.] |
|
|
|
| Revelation Biosciences, Inc. announced the site initiation for its Phase IIb viral challenge study to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza in healthy humans.
[Revelation Biosciences, Inc.] |
|
|
|
|
| January 21 -23, 2022
Austin, Texas, United States |
|
|
|
|
|
| | London School of Hygiene & Tropical Medicine – London, England, United Kingdom |
|
|
|
| | King’s College London – London, England, United Kingdom |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | University Medical Center Freiburg – Freiburg, Germany |
|
|
|
| | The Henry M. Jackson Foundation for the Advancement of Military Medicine – Silver Spring, Mayland, United States |
|
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
